Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Hosp Pediatr ; 12(2): 190-198, 2022 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-35075483

RESUMO

BACKGROUND: The microbiologic etiologies, clinical manifestations, and antimicrobial treatment of neonatal infections differ substantially from infections in adult and pediatric patient populations. In 2019, the Centers for Disease Control and Prevention developed neonatal-specific (Standardized Antimicrobial Administration Ratios SAARs), a set of risk-adjusted antimicrobial use metrics that hospitals participating in the National Healthcare Safety Network's (NHSN's) antimicrobial use surveillance can use in their antibiotic stewardship programs (ASPs). METHODS: The Centers for Disease Control and Prevention, in collaboration with the Vermont Oxford Network, identified eligible patient care locations, defined SAAR agent categories, and implemented neonatal-specific NHSN Annual Hospital Survey questions to gather hospital-level data necessary for risk adjustment. SAAR predictive models were developed using 2018 data reported to NHSN from eligible neonatal units. RESULTS: The 2018 baseline neonatal SAAR models were developed for 7 SAAR antimicrobial agent categories using data reported from 324 neonatal units in 304 unique hospitals. Final models were used to calculate predicted antimicrobial days, the SAAR denominator, for level II neonatal special care nurseries and level II/III, III, and IV NICUs. CONCLUSIONS: NHSN's initial set of neonatal SAARs provides a way for hospital ASPs to assess whether antimicrobial agents in their facility are used at significantly higher or lower rates compared with a national baseline or whether an individual SAAR value is above or below a specific percentile on a given SAAR distribution, which can prompt investigations into prescribing practices and inform ASP interventions.


Assuntos
Antibacterianos , Hospitais , Adulto , Antibacterianos/uso terapêutico , Centers for Disease Control and Prevention, U.S. , Criança , Atenção à Saúde , Humanos , Recém-Nascido , Estados Unidos
2.
Am J Infect Control ; 48(4): 443-445, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-31761293

RESUMO

This case study is part of a series centered on the Centers for Disease Control and Prevention's National Healthcare Safety Network (NHSN) health care-associated infection (HAI) surveillance definitions. The intent of the case study series is to foster standardized application of the NHSN HAI surveillance definitions among infection preventionists and to promote accurate determination of HAI events. These cases reflect some of the complex patient scenarios that infection preventionists have encountered in their daily surveillance of HAIs using NHSN definitions. Objectives have been previously published.1.


Assuntos
Centers for Disease Control and Prevention, U.S./organização & administração , Infecção Hospitalar/prevenção & controle , Confiabilidade dos Dados , Instalações de Saúde , Controle de Infecções/métodos , Publicações Periódicas como Assunto , Humanos , Qualidade da Assistência à Saúde , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...